Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeting inflammation in depression using minocycline
2020-005162-33Phase 2Active
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of minocycline in treatment-resistant depression (TRD), sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli. Primary endpoint: Improvement of depressive symptomatology. Started Aug 2023; status: active.
02
Drugs
minocycline
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on 2020-005162-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005162-33.